The Covid-19 pandemic is a major public health issue. Potential treatments are essential to control the infection. Hydroxychlorquine is currently tested in several clinical trials to evaluate its efficiency.The objective of this study was to evaluate the symptoms related to COVID-19 occuring in patients with systemic lupus erythematosus (SLE)
Introduction:The Covid-19 pandemic has had a major impact on many countries on the sanitary
and economic level. Finding an efficient cure is paramount in order to reduce its severity
and mortality. Several medications are currently under investigation. Among them,
hydroxychloroquine can prevent viral replication at several sites and has been shown
efficient in vitro. Several clinical trials are in progress to evaluate its efficiency in
vivo. However, no study so far has evaluated the covid-19 infection in patients with SLE.
Objectives and methods: The primary objective was to describe the prevalence and the severity
of Covid-19 infection in patients wih systemic lupus erythematosus. The secondary objective
was to compare these parameters in patients treated by hydroxychloroquine and those not
treated by hydroxychloroquine. This observational study of a historical-prospective cohort
focuses on all adult lupus patients seen during the last year in the departments of
rheumatology and nephrology in CHU Montpellier. It will collect information concerning the
patient's condition, treatments and main comorbidities (cardio-vascular, respiratory, hepatic
and immune depression), as well as symptoms suggesting covid-19 infection, its confirmation
and its course and severity.
Inclusion criteria:
- adult patient with systemic lupus erythematosus seen during the last year in the
departments of rheumatology or nephrology
Exclusion criteria:
- patient not speaking french nor english
Uhmontpellier
Montpellier, France
Christian JORGENSEN, Resident, Study Director
University Hospital, Montpellier